HHSC to Add New Qulipta® Indication to Clinical Prior Authorization

Date: June 20, 2023

Attention: All Providers

Effective Date: June 27, 2023

Call to action:Texas Children’s Health Plan (TCHP) would like to let providers know that effective June 27, 2023, Texas Health and Human Services (HHSC) will follow the Food and Drug Administration’s recent approval of new indication for atogepant (Qulipta^®), to prevent chronic migraine in adults.

How this impacts providers: Starting June 27, 2023, TCHP will implement the new indication for atogepant (Qulipta^®) to prevent chronic migraine in adults. The new criteria is available on the HHSC website and can be viewed here: Calcitonin Gene-Related Peptide Receptor (CGRP).

Next steps for providers: Prescribers should share this communication with their staff. Provider must submit documentation, including but not limited to: office chart notes, lab results, pertinent clinical information, etc. supporting that the member has met all appropriate criteria in support for Qulipta^® approval.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.